117 related articles for article (PubMed ID: 29492857)
1. Acceptability of Liquid Human Growth Hormone (hGH) [Norditropin Simple Xx®] in Adults and Children with GH Deficiency and Children with Chronic Renal Disease.
Drent ML; Jakobsdottir S; van Wijk JAE; Oostdijk W; Wit JM
Clin Drug Investig; 2002 Sep; 22(9):633-638. PubMed ID: 29492857
[TBL] [Abstract][Full Text] [Related]
2. Norditropin SimpleXx: a liquid human growth hormone formulation, a pen system and an auto-insertion device.
Müller J; Skakkebaek NE; Jacobsen BB; Keller E; Heinrich U; Hartmann K; Hokken-Koelega AC; Delemarre van de Waal HA
Horm Res; 1999; 51 Suppl 3():109-12. PubMed ID: 10592453
[TBL] [Abstract][Full Text] [Related]
3. An open-label acceptability study of Norditropin SimpleXx--a new liquid growth hormone formulation.
Stanhope R; Buchanan C; Butler G; Costigan C; Dunger D; Greene S; Hoey H; Hughes I; Kelnar C; Kirk J; Komulainen J; Lowry M; Warner J
J Pediatr Endocrinol Metab; 2001 Jun; 14(6):735-40. PubMed ID: 11453523
[TBL] [Abstract][Full Text] [Related]
4. The clinical usefulness of liquid human growth hormone (hGH) (Norditropin SimpleXx in the treatment of GH deficiency.
Iyoda K; Moriwake T; Seino Y; Niimi H
Horm Res; 1999; 51 Suppl 3():113-5. PubMed ID: 10592454
[TBL] [Abstract][Full Text] [Related]
5. Liquid growth hormone: preservatives and buffers.
Kappelgaard AM; Bojesen A; Skydsgaard K; Sjögren I; Laursen T
Horm Res; 2004; 62 Suppl 3():98-103. PubMed ID: 15539807
[TBL] [Abstract][Full Text] [Related]
6. Ease of use and acceptability of a new pen device for the administration of growth hormone therapy in pediatric patients: an open-label, uncontrolled usability test.
Fuchs GS; Mikkelsen S; Knudsen TK; Kappelgaard AM
Clin Ther; 2009 Dec; 31(12):2906-14. PubMed ID: 20110030
[TBL] [Abstract][Full Text] [Related]
7. Patient preference for a new growth hormone injection device: results of an open-label study in Japanese pediatric patients.
Kappelgaard AM; Mikkelsen S; Knudsen TK; Fuchs GS
J Pediatr Endocrinol Metab; 2011; 24(7-8):489-96. PubMed ID: 21932587
[TBL] [Abstract][Full Text] [Related]
8. Children and adolescent acceptability of a new device system to administer human growth hormone--a pilot study.
Kappelgaard AM; Mikkelsen S; Bagger C; Fuchs GS
J Pediatr Endocrinol Metab; 2012; 25(3-4):285-94. PubMed ID: 22768658
[TBL] [Abstract][Full Text] [Related]
9. Product wastage from modern human growth hormone administration devices: a laboratory and computer simulation analysis.
Pollock RF; Qian Y; Wisniewski T; Seitz L; Kappelgaard AM
Med Devices (Auckl); 2013; 6():107-14. PubMed ID: 23946672
[TBL] [Abstract][Full Text] [Related]
10. Treatment adherence with the easypod™ growth hormone electronic auto-injector and patient acceptance: survey results from 824 children and their parents.
Bozzola M; Colle M; Halldin-Stenlid M; Larroque S; Zignani M;
BMC Endocr Disord; 2011 Feb; 11():4. PubMed ID: 21294891
[TBL] [Abstract][Full Text] [Related]
11. Growth hormone therapy with norditropin ( somatropin ) in growth hormone deficiency.
Pawlikowska-Haddal A
Expert Opin Biol Ther; 2013 Jun; 13(6):927-32. PubMed ID: 23662811
[TBL] [Abstract][Full Text] [Related]
12. The growth hormone cascade: progress and long-term results of growth hormone treatment in growth hormone deficiency.
Grumbach MM; Bin-Abbas BS; Kaplan SL
Horm Res; 1998; 49 Suppl 2():41-57. PubMed ID: 9730672
[TBL] [Abstract][Full Text] [Related]
13. Understanding and meeting the needs of those using growth hormone injection devices.
Dumas H; Panayiotopoulos P; Parker D; Pongpairochana V
BMC Endocr Disord; 2006 Oct; 6():5. PubMed ID: 17034628
[TBL] [Abstract][Full Text] [Related]
14. Attenuation of Human Growth Hormone-Induced Rash With Graded Dose Challenge.
Mann J; Caruana D; Luo E; Gottesman E; Agrawal N; Lozeau D; Hessel J; Neumann M; Khanijo S; Hasan Z; Rizvi K; Gunther R; Donovan D; Chan D; Lee-Wong M; Szema AM
Cureus; 2022 Aug; 14(8):e27920. PubMed ID: 36110455
[TBL] [Abstract][Full Text] [Related]
15. Multi-centre phase IV trial to investigate the immunogenicity of a new liquid formulation of recombinant human growth hormone in adults with growth hormone deficiency.
Johannsson G; Nespithal K; Plöckinger U; Alam V; McLean M
J Endocrinol Invest; 2018 Aug; 41(8):919-927. PubMed ID: 29488103
[TBL] [Abstract][Full Text] [Related]
16. Clinicians' Feedback on Patient/Carer Experience After Switching of Growth Hormone Treatment in Pediatric Patients During COVID-19.
Blair J; Warth K; Suvarna Y; Cappa M
Patient Prefer Adherence; 2021; 15():2113-2123. PubMed ID: 34584405
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy and safety of recombinant human growth hormone solution in children with growth hormone deficiency in China: a multicenter trial].
Hou L; Luo XP; Du ML; Ma HM; Gong CX; Li YC; Shen SX; Zhao ZH; Liang L; Dong GP; Yan CY; Du HW
Zhonghua Er Ke Za Zhi; 2009 Jan; 47(1):48-52. PubMed ID: 19573383
[TBL] [Abstract][Full Text] [Related]
18. A new pen device for injection of recombinant human growth hormone: a convenience, functionality and usability evaluation study.
Sauer M; Abbotts C
Patient Prefer Adherence; 2018; 12():27-34. PubMed ID: 29343946
[TBL] [Abstract][Full Text] [Related]
19. User assessment of Norditropin NordiFlex(®), a new prefilled growth hormone pen: a Phase IV multicenter prospective study.
Tauber M; Jaquet D; Jesuran-Perelroizen M; Petrus M; Bertrand AM; Coutant R;
Patient Prefer Adherence; 2013; 7():455-62. PubMed ID: 23737664
[TBL] [Abstract][Full Text] [Related]
20. Ease of use and preference for a new disposable self-injection pen compared with a reusable pen for administering recombinant human growth hormone: A multicenter, 2-month, single-arm, open-label clinical trial in patient-caregiver dyads.
Hey-Hadavi J; Pleil A; Deeb LC; Fuqua JS; Silverman LA; Reiner B; Newfield R; Rajicic N; Wajnrajch MP; Cara JF
Clin Ther; 2010 Nov; 32(12):2036-47. PubMed ID: 21118739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
